Arcutis生物治疗学击败了Q3收入估计数,尽管损失、股本增加、机构兴趣增加。 Arcutis Biotherapeutics beat Q3 earnings estimates despite losses, boosting stock and institutional interest.

Arcutis生物治疗公司(ARQT)报告,尽管利润指数为负值,但质量3的收益好于预期,每股0.6美元,收入为9 922万美元,超过了估计值。 Arcutis Biotherapeutics (ARQT) reported better-than-expected Q3 earnings of $0.06 per share and $99.22 million in revenue, surpassing estimates, despite negative profitability metrics. 该公司在对皮质病等皮肤病进行热门治疗时,增加了机构所有权,包括Perpetual Ltd. Wall Street Zen公司将ARQT从“Strong-Buy”降为“Buy”,但分析师仍然持有“Moderate Buy”共识,目标为29.00美元。 The company, developing topical treatments for skin conditions like psoriasis, saw increased institutional ownership, including a major stake rise by Perpetual Ltd. Wall Street Zen downgraded ARQT from “Strong-Buy” to “Buy,” though analysts still hold a “Moderate Buy” consensus with a $29.00 target. 股票关闭26.20美元,市场上限为32.1亿美元,贝塔为1.71美元。 The stock closed at $26.20, with a market cap of $3.21 billion and a beta of 1.71.